We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
US-based biotechnology company RXi Pharmaceuticals has formed a research alliance with the Karolinska Institutet in Stockholm, Sweden, to develop and improve immuno-oncology treatments for solid tumours.
RXi Pharmaceuticals has been granted a patent from the United States Patent and Trademark Office (USPTO) for the methods of use of sd-rxRNAs targeting Connective Tissue Growth Factor (CTGF) for the treatment or prevention of fibrotic disorders,